April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
The Clear (combination (of) Lutein Effects (on) Aging Retina) Study; Lutein Supplementation Improves Visual Acuity And Night Vision In Early Amd; A Two-centre, Placebo-controlled Study
Author Affiliations & Notes
  • Tos TJM Berendschot
    University Eye Clinic Maastricht, Maastricht, The Netherlands
  • Maria Makridaki
    Optometry, University of Manchester, Agios Nikolaos, Crete, Greece
  • Rob LP van der Veen
    University Eye Clinic Maastricht, Maastricht, The Netherlands
  • Neil RA Parry
    Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom
  • Dave Carden
    Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom
  • Ian J Murray
    Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom
  • Footnotes
    Commercial Relationships  Tos TJM Berendschot, Cognis GmbH (F); Maria Makridaki, Cognis GmbH (F); Rob LP van der Veen, Cognis GmbH (F); Neil RA Parry, None; Dave Carden, None; Ian J Murray, Cognis GmbH (F)
  • Footnotes
    Support  UK Medical research Council
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 3631. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Tos TJM Berendschot, Maria Makridaki, Rob LP van der Veen, Neil RA Parry, Dave Carden, Ian J Murray; The Clear (combination (of) Lutein Effects (on) Aging Retina) Study; Lutein Supplementation Improves Visual Acuity And Night Vision In Early Amd; A Two-centre, Placebo-controlled Study. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3631. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine the effect on photopic (visual acuity) and scotopic (dark adaptation) vision of enhancing macular pigment optical density (MPOD) with lutein (L) capsules in patients with early AMD.

Methods: : A randomised, placebo-controlled two-centred, 12 month study of the effects of L supplementation was conducted in Manchester, UK and Maastricht, The Netherlands. L capsules (10mg Ester), or a placebo were taken daily. 71 patients were randomly assigned to either L (lutein, n=34, mean age 71.7 ± 8.7 ) or P (placebo, n=37, mean age 69.1 ± 8.5) groups. Best corrected Log MAR visual acuities, dark adaptation and MPOD were measured at baseline and on three, four month intervals, after the start of the 12 month supplementation period. MPOD was measured using a flicker-based technique. VA data were analysed only for patients with VA>0.06 (L group n=19, P group n=16).

Results: : MPOD increased from 0.38 ± 0.19 to 0.53 ± 0.22 OD units (p0.06, VA improved from 0.23 ± 0.12 (baseline) to 0.16 ± 0.10 (visit 4) in the L group (p=0.004). In the P group there was a non-significant deterioration in VA from 0.18 ± 0.12 to 0.20 ± 0.12. The mean difference in VA between baseline and visit 4 for the L group was 0.07 ± 0.10 and for the P group was -0.03 ± 0.10 (p<0.001). The mean rod recovery rate for the L group was 3.1 ± 1.1 dB/min at baseline and this increased to 3.7 ± 1.7 dB/min at visit 4 (p=0.017). The mean rod recovery rate for the P group was reduced from 3.3 ±1.3 dB/min to 3.1 ±1.35 dB/min (NS).

Conclusions: : Lutein supplementation over a 12 months period increased MPOD levels in AMD patients. In some, but not all patients, this increase in MPOD was accompanied by an improvement in VA. In those with VA>0.06, 56% improved VA by more than 1 line.

Clinical Trial: : http://www.clinicaltrials.gov NCT01042860

Keywords: macular pigment • age-related macular degeneration • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×